24 results
424B5
CERE
Cerevel Therapeutics Holdings Inc
12 Oct 23
Prospectus supplement for primary offering
4:16pm
-week ambulatory blood pressure monitoring trial providing clear evidence that emraclidine does not induce an increase in blood pressure with chronic
424B5
CERE
Cerevel Therapeutics Holdings Inc
11 Oct 23
Prospectus supplement for primary offering
4:08pm
not induce an increase in blood pressure with chronic dosing in people living with schizophrenia.
In addition, we plan to evaluate the potential
8-K
EX-99.1
tqv 3iqc7
3 May 23
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
6:39am
8-K
EX-99.1
8fcy4b h7q059w79
19 Dec 22
Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial
8:00am
424B4
kuegsxv 4yrqmftk4o
2 Jul 21
Prospectus supplement with pricing info
5:22pm
424B3
fxwfbp jkdr
29 Jun 21
Prospectus supplement
6:57am
8-K
EX-99.1
4btr1girf
29 Jun 21
Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b
6:52am
DRS
l31wbm1co4dtk54
27 May 21
Draft registration statement
12:00am
424B3
q0j00hes51 gr2xd
26 Mar 21
Prospectus supplement
4:31pm
POS AM
a7i0naimrj
24 Mar 21
Prospectus update (post-effective amendment)
5:13pm
10-K
w8laoezm fr2xjv2w9
24 Mar 21
Annual report
4:20pm
424B3
23x4l
4 Dec 20
Prospectus supplement
4:58pm